Aequus Signs Exclusive Distribution Agreement with SCOPE Ophthalmics for Canadian Distribution Rights of Dry Eye Products streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Aequus sees fiscal 2020 revenue rise by 59%, driven by strong sales of Vistitan and Tacrolimus
For the year ended December 31, 2020, it reported revenue of $2.6 million, compared to $1.6 million during the year ended December 31, 2019 COO Grant Larsen said that Vistitan revenue at +15% and Tacrolimus at +49% showed strong consistent growth
Aequus Pharmaceuticals Inc. (CVE:AQS) (OTCQB:AQSZF) (FRA:AEQ) posted fiscal 2020 results that saw its annual revenue jump 59% year-over-year on the back of strong sales led by PRVistitan and Tacrolimus eye treatments.
For the year ended December 31, 2020, the Vancouver, British Columbia-based specialty pharmaceutical company reported its highest annual revenue to date of $2.6 million, up 59%, compared to $1.6 million during the year ended December 31, 2019. The company chalked the bump in revenue to higher sales.
Aequus Pharmaceuticals Inc bringing diverse pipeline of new drugs to the Canadian market proactiveinvestors.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.co.uk Daily Mail and Mail on Sunday newspapers.